Evaluating LLMs for Temporal Entity Extraction from Pediatric Clinical Text in Rare Diseases Context
Abstract
The aim of this work is to extract Temporal Entities from patients’ EHR from pediatric hospital specialising in Rare Diseases, thus allowing to create a patient timeline relative to diagnosis . We aim to perform an evaluation of NLP tools and Large Language Models (LLM) to test their application in the field of clinical study where data is limited and sensitive. We present a short annotation guideline for temporal entity identification. We then use the tool EDS-NLP, the Language Model CamemBERT-with-Dates and the LLM Vicuna to extract temporal entities. We perform experiments using three different prompting techniques on the LLM Vicuna to evaluate the model thoroughly. We use a small dataset of 50 EHR describing the evolution of rare diseases in patients to perform our experiments. We show that among the different methods to prompt a LLM, using a decomposed structure of prompting method on the LLM vicuna produces the best results for temporal entity recognition. The LLM learns from examples in the prompt and decomposing one prompt to several prompts allows the model to avoid confusions between the different entity types. Identifying the temporal entities in EHRs helps to build the timeline of a patient and to learn the evolution of a diseases. This is specifically important in the case of rare diseases due to the availability of limited examples. In this paper, we show that this can be made possible with the use of Language Models and LLM in a secure environment, thus…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.